Questdquestd

a16z Bio + Health: early-stage portfolio

101 companies a16z's Bio + Health team first backed at seed or venture stage. They were 21.2% of a16z's new early-stage companies in 2023–2026, up from 15.2% in 2019–2022. Of those backed by 2021, a16z lists 26% as exited (7 IPOs, 9 acquisitions).

Early-stage companies
101
Share, 2023–2026
21.2%
Entered at seed
60%
Exited (backed by 2021)
26%

Share of new early-stage companies, by year

Bio + Health companies, newest first

101 companies

Source: a16z’s public portfolio and speedrun directories; each company links to its a16z page. See how we count, or browse open problems worth solving.

Frequently asked questions

How many early-stage companies has a16z Bio + Health backed?

a16z's public portfolio lists 101 Bio + Health companies it first backed at seed or venture stage. The list is a selection of a16z's investments, so the true number may be higher.

Is a16z investing more in Bio + Health?

Bio + Health was 21.2% of the early-stage companies a16z first backed in 2023–2026, compared with 15.2% in 2019–2022. Recent years are incomplete because a16z adds investments to its list with a delay.